Research ArticleOpen AccessGoogle Scholar indexed
The Evaluation of Tolvaptan Therapy and Long-Term Prognosis in Hepatocellular Carcinoma with Refractory Ascites
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 1 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 2 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 3 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 4 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 5 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 6 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 7 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 8 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
- 9 Department of Gastroenterology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
Open Journal of Gastroenterology·Volume 08 (2018)·Pages 39–44·Published 12 February 2018·DOI10.4236/ojgas.2018.82004
Copy link · social · email
Abstract
We investigated Tolvaptan efficacy and long-term prognosis with focus on nutrition in 20 patients with refractory hepatic ascites in hepatocellular carcinoma (HCC). Bloating improved in 55% of patients, as determined using a Japanese version of the Support Team Assessment Schedule. Nutritional status improved with Tolvaptan treatment, based on the Controlling Nutritional Status score and Onodera’s prognostic nutritional index. Long-term prognosis was better in responders than in non-responders (mean survival time: 308 days vs. 97 days, p = 0.031). Tolvaptan was even effective in many patients with HCC, with additional improvement in long-term prognosis expected with improvement in the nutritional status.
KeywordsTolvaptanHepatic AscitesSarcopeniaLoop DiureticsLong-Term Prognosis
- Sola, E., Watson, H., Graupera, .I, et al. (2012) Factors Related to Quality of Life in Patients with Cirrhosis and Ascites: Relevance of Serum Sodium Concentration and Leg Edema. Journal of Hepatology, 57, 1199-1206. https://doi.org/10.1016/j.jhep.2012.07.020
- Llach, J., Gines, P., Arroyo, V., et al. (1988) Prognostic Value of Arterial Pressure, Endogenous Vasoactive Systems, and Renal Function in Cirrhotic Patients Admitted to the Hospital for the Treatment of Ascites. Gastroenterology, 94, 482-487. https://doi.org/10.1016/0016-5085(88)90441-6
- Larramona, G.L., Lucendo, A.J. and Tenias, J.M. (2015) Association between Nutritional Screening via the Controlling Nutritional Status Index and Bone Mineral Density in Chronic Liver Disease of Various Etiologies. Hepatology Research, 45, 618-628. https://doi.org/10.1111/hepr.12395
- Yamamura, Y., Nakamura, S., Itoh, S., et al. (1998) OPC-41061, a Highly Potent human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. Journal of Pharmacology and Experimental Therapeutics, 287, 860-867.
- Ohki, T., Sato, K., Yamada, T., et al. (2015) Efficacy of Tolvaptan in Patients with Refractory Ascites in a Clinical Setting. World Journal of Hepatology, 7, 1685-1693. https://doi.org/10.4254/wjh.v7.i12.1685
- Sakaida, I., Kawazoe, S., Kajimura, K., et al. (2014) Tolvaptan for Improvement of Hepatic Edema: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Hepatology Research, 44, 73-82. https://doi.org/10.1111/hepr.12098
- Sakaida, I., Terai, S., Kurosaki, M., et al. (2017) Effectiveness and Safety of Tolvaptan in Liver Cirrhosis Patients with Edema: Interim Results of Post-Marketing Surveillance of Tolvaptan in Liver Cirrhosis (START Study). Hepatology Research, 47, 1137-1146. https://doi.org/10.1111/hepr.12852
- Miyashita, M., Matoba, K., Sasahara, T., et al. (2004) Reliability and Validity of Japanese Version STAS (STAS-J). Palliative and Supportive Care, 2, 379-384. https://doi.org/10.1017/S1478951504040507
- Hiramine, Y., Uojima, H., Nakanishi, H., et al. (2017) Response Criteria of Tolvaptan for the Treatment of Hepatic Edema. Journal of Gastroenterology.
- Ignacio de Ulibarri, J., Gonzalez-Madrono, A., de Villar, N.G., et al. (2005) CONUT: A Tool for Controlling Nutritional Status. First Validation in a Hospital Population. Nutricion Hospitalaria, 20, 38-45.